R-Pharm, a leading developer of pharmaceutical solutions, carries out the full production cycle of the anti-tumor drug Arvestio®, from the substance to the finished dosage form.
The drug contains bevacizumab, a humanized monoclonal antibody that selectively blocks human vascular endothelial growth factor (VEGF).
The drug is used to treat various oncological diseases, including breast cancer, cervical cancer, colorectal cancer, glioblastoma, and other malignancies. It is included in the list of vital and essential drugs (VED).
Arvesto® received the Made in Russia certificate in the reliability category to join the national brand export promotion program implemented by Russian Export Center (part of VEB.RF). The program is coordinated by the Russian Ministry of Industry and Trade.
"This is not only recognition of quality but also a step toward the global promotion of Russian pharmaceutical solutions. Under the Made in Russia brand, we unite the most reliable exporters offering unique products to the world. And we are pleased that products like Arvesto help shape Russia's image," Alexey Solodov, Vice President, Russian Export Center.
The certificate is awarded to products and services with improved characteristics and higher quality. It demonstrates the manufacturer's reliability and the safety of the product, which is especially important for promotion in international markets.
This is already the fourth Made in Russia certificate for the R-Pharm line of drugs from the VED list. Previously, it was awarded to Artlegia, Arcerix and Arfleyda.
The drug contains bevacizumab, a humanized monoclonal antibody that selectively blocks human vascular endothelial growth factor (VEGF).
The drug is used to treat various oncological diseases, including breast cancer, cervical cancer, colorectal cancer, glioblastoma, and other malignancies. It is included in the list of vital and essential drugs (VED).
Arvesto® received the Made in Russia certificate in the reliability category to join the national brand export promotion program implemented by Russian Export Center (part of VEB.RF). The program is coordinated by the Russian Ministry of Industry and Trade.
"This is not only recognition of quality but also a step toward the global promotion of Russian pharmaceutical solutions. Under the Made in Russia brand, we unite the most reliable exporters offering unique products to the world. And we are pleased that products like Arvesto help shape Russia's image," Alexey Solodov, Vice President, Russian Export Center.
The certificate is awarded to products and services with improved characteristics and higher quality. It demonstrates the manufacturer's reliability and the safety of the product, which is especially important for promotion in international markets.
This is already the fourth Made in Russia certificate for the R-Pharm line of drugs from the VED list. Previously, it was awarded to Artlegia, Arcerix and Arfleyda.